Francisco Silva - Mar 20, 2023 Form 4 Insider Report for BioRestorative Therapies, Inc. (BRTX)

Role
VP of Research and Development, Director, 10%+ Owner
Signature
/s/ Francisco Silva
Stock symbol
BRTX
Transactions as of
Mar 20, 2023
Transactions value $
-$19,649
Form type
4
Date filed
3/22/2023, 04:49 PM
Previous filing
Feb 28, 2023
Next filing
Apr 4, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BRTX Common Stock Tax liability -$19.6K -6.73K -4.06% $2.92 159K Mar 20, 2023 Direct F1, F2
holding BRTX Common Stock 12.1K Mar 20, 2023 IRA

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BRTX Stock Option 1 Mar 20, 2023 Common Stock 1 $3,000.00 Direct F3
holding BRTX Stock Option 3 Mar 20, 2023 Common Stock 3 $3,000.00 Direct F3
holding BRTX Stock Option 1 Mar 20, 2023 Common Stock 1 $3,000.00 Direct
holding BRTX Stock Option 9 Mar 20, 2023 Common Stock 9 $3,000.00 Direct F3
holding BRTX Stock Option 6 Mar 20, 2023 Common Stock 6 $3,000.00 Direct F3
holding BRTX Stock Option 15 Mar 20, 2023 Common Stock 15 $3,000.00 Direct F3
holding BRTX Stock Option 20 Mar 20, 2023 Common Stock 20 $3,000.00 Direct F3
holding BRTX Stock Option 25 Mar 20, 2023 Common Stock 25 $3,000.00 Direct F3
holding BRTX Stock Option 293K Mar 20, 2023 Common Stock 293K $5.08 Direct F4
holding BRTX Stock Option 42.1K Mar 20, 2023 Common Stock 42.1K $5.08 Direct F5
holding BRTX Stock Option 107K Mar 20, 2023 Common Stock 107K $2.91 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were withheld from vested stock grant to pay the associated withholding taxes.
F2 Includes 48,912 shares received pursuant to an unvested restricted stock unit grant. Such shares vest on March 18, 2024.
F3 The option is currently exercisable.
F4 The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 and 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
F5 The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 and 21,029 shares in eight nearly equal quarterly installments beginning on November 4, 2022 and continuing every three months thereafter until fully vested.
F6 The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning on February 17, 2024 and continuing every three months thereafter until fully vested.